ArticleProstate cancer and prostatic diseases2022
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency.
Article in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Minimally invasive treatments for benign prostatic hyperplasia in patients over 75: a systematic review.World journal of urology · 2025Pooled it
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature.World journal of urology · 2023Pooled it
- Real-world comparison of RezūmWorld journal of urology · 2026Article
- Patients with frailty, benign prostatic hyperplasia and indwelling bladder catheter: What are the 1-year outcomes after Rezūm therapy?Current urology · 2025Article
- Postoperative Outcomes Following Rezum: A Novel Minimally Invasive Therapy for Benign Prostatic Hyperplasia (BPH).Cureus · 2025Article
- To Rezūm or Not to Rezūm: A Narrative Review of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia.Journal of clinical medicine · 2025Review
- Real-world experience of water vapour therapy (Rezum) in patients with benign prostatic enlargement: a retrospective single-center study.Prostate cancer and prostatic diseases · 2025Article
- Comparative study of HoLEP in elderly patients with indwelling catheters: a retrospective dual-center study.World journal of urology · 2025Article
- Feasibility assessment of catheter-free water vapor thermal therapy for treatment of benign prostatic hyperplasia.World journal of urology · 2024Article
- Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men.Prostate cancer and prostatic diseases · 2024Article
- Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.Prostate cancer and prostatic diseases · 2024Review
- Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate.Prostate cancer and prostatic diseases · 2024Article
- Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience.World journal of urology · 2024Article
- Procedural Intervention for Benign Prostatic Hyperplasia in Men ≥ Age 70 Years - A Review of Published Literature.Clinical interventions in aging · 2023Review
- Robotic simple prostatectomy vs HOLEP, a 'multi single-center' experiences comparison.Central European journal of urology · 2023Article
- Article
- Transurethral resection of the prostate in 85+ patients: a retrospective, multicentre study.World journal of urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWater vapor thermal therapy (Rezūm) is a minimally invasive treatment for benign prostatic enlargement (BPE). We report on safety and efficacy of this method for treatment of recurrent urinary retention and relief of catheter dependency owing to BPE in multimorbid patients, considered unfit for surgery.
methodsWe retrospectively evaluated 136 patients with recurrent urinary retention who underwent water vapor therapy in an ambulatory setting with periprostatic block and optional sedation between 11/2017 and 02/2021 in three urological departments. The objective was successful catheter withdrawal and continuing catheter independency after 3- and 12-months following treatment.
resultsMean patient age was 80.3 years (±7.8), mean prostate volume 54 ml (±27.3), and mean catheter dependency before treatment was 4.8 months (±6.0). ASA classification was a followed: II: 10%, III: 71%, and IV: 19%. All procedures were performed successfully in an ambulatory setting. Perioperative complications were infrequent and minor (Clavien-Dindo Grade 1-2) and included haematuria in 4.4% and urinary tract infection in 3.9% of all cases. A total of 103 patients (78.6%) were able to void spontaneously after a median of 31 days. No significant differences in age, prostate volume, duration of catheter dependency, vapor injections, and ASA score were found between patients with successful or unsuccessful outcome. The mean follow-up period was 6.1 months (±5.9, range 1-22 months). A 3-month follow-up was available for 77 patients (75%) and 34 patients (33%) were followed for 12 months. After 3 and 12 months, 93.5 and 91% of patients remained catheter independent. Fifteen patients (11%) died during follow-up, with a mean overall survival of 7.7 months (±4.7).
conclusionsWater vapor therapy may prove to be a useful, minimally invasive treatment in a multimorbid population with catheter dependency after urinary retention, secondary to BPE, considered at highest risk or unfit for surgery. Future studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.